Trial Profile
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 12 Feb 2023 Results of 12-week were published in the Cardiology and Therapy.
- 19 Jan 2021 Status changed from active, no longer recruiting to discontinued.
- 27 May 2020 Planned End Date changed from 23 Oct 2020 to 6 Sep 2021.